Steven Etoch
Stephens Inc., Research Division
[Audio Gap]
Is intended to be more of a fireside chat, so I’ll stop along the way and poll for any questions. So feel free to chime in as needed. And with that, I’ll turn it over to you all for any opening comments that you want to make, and we’ll launch into Q&A.
James Hippel
Executive VP of Finance & CFO
Yes, sure. Thank you, Mac. It’s always a pleasure to be here. Stephens is always one of our favorite conferences to attend. Just real quickly, I can maybe start off with just some of the highlights for the quarter for us that we just finished in Q1.
If we look, first of all, our pharma end market continue to perform very well for us. We had double-digit growth in pharma for the third quarter in a row. That represents roughly 30% of our revenue for those keeping score. We saw continued strength in our — or I should say, we saw some rebound and strength in our key core pillars, growth pillars, that being our ProteinSimple franchise, third or fourth straight quarter of double-digit consumable growth. And we saw momentum pick up on the instruments in the back half of the quarter into October, very encouraging to see.
Our spatial biology franchise also appears to be turning the corner. As a reminder, our spatial franchise is probably the most heavily indexed of our product portfolio to academic and small biotechs, which have been the most — end markets under the most pressure. And as
